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Background. In 2010, the World Health Organization (WHO) released revised guidelines for prevention of
mother-to-child human immunodeﬁciency virus (HIV) transmission (PMTCT). We projected clinical impacts,
costs, and cost-effectiveness of WHO-recommended PMTCT strategies in Zimbabwe.
Methods. We used Zimbabwean data in a validated computer model to simulate a cohort of pregnant, HIV-
infected women (mean age, 24 years; mean CD4 count, 451 cells/µL; subsequent 18 months of breastfeeding).
We simulated guideline-concordant care for 4 PMTCT regimens: single-dose nevirapine (sdNVP); WHO-
recommended Option A, WHO-recommended Option B, and Option B+ (lifelong maternal 3-drug antiretroviral
therapy regardless of CD4). Outcomes included maternal and infant life expectancy (LE) and lifetime healthcare
costs (2008 US dollars [USD]). Incremental cost-effectiveness ratios (ICERs, in USD per year of life saved [YLS])
were calculated from combined (maternal +infant) discounted costs and LE.
Results. Replacing sdNVP with Option A increased combined maternal and infant LE from 36.97 to 37.89
years and would reduce lifetime costs from $5760 to $5710 per mother–infant pair. Compared with Option A,
Option B further improved LE (38.32 years), and saved money within 4 years after delivery ($5630 per mother–
infant pair). Option B+ (LE, 39.04 years; lifetime cost, $6620 per mother–infant pair) improved maternal and
infant health, with an ICER of $1370 per YLS compared with Option B.
Conclusions. Replacing sdNVP with Option A or Option B will improve maternal and infant outcomes and
save money; Option B increases health beneﬁts and decreases costs compared with Option A. Option B+further
improves maternal outcomes, with an ICER (compared with Option B) similar to many current HIV-related
healthcare interventions.
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430 ￿ CID 2013:56 (1 February) ￿ HIV/AIDStransmission (PMTCT) can reduce perinatal HIV transmission
to <2% in the absence of breastfeeding and to <5% by 6
months of age among breastfeeding infants [1–3]. As a result,
the World Health Organization (WHO) has called for the
“virtual elimination” of pediatric HIV [1–3]. Access to antire-
troviral medications (ARVs) for PMTCT remains limited,
however; only 59% of HIV-infected pregnant women received
ARVs for PMTCT in 2010 [4]. As a result, nearly 400000 new
infant HIV infections occur annually, and HIV-infected women
experience high postpartum morbidity and mortality [4–6].
In 2010, WHO issued revised guidelines for PMTCT [1].
Theguidelinesincluded arenewedemphasison identiﬁcationof
pregnant, HIV-infected women with CD4 count ≤350 cells/µL
or WHO stage 3–4 disease, who require lifelong 3-drug anti-
retroviral therapy (ART) for treatment of their own HIV infec-
tions and for PMTCT. For women with less-advanced disease,
WHO recommends a country- or program-level choice
between Option A (maternal zidovudine in pregnancy; infant
nevirapine [NVP] throughout breastfeeding), and Option B
(maternal 3-drug ARV regimens throughout pregnancy and
breastfeeding, with interruption after weaning). Select pro-
grams are considering Option B+, in which maternal 3-drug
regimens are initiated in pregnancy (regardless of maternal
CD4) and continued throughout life, including throughout
breastfeeding and subsequent pregnancies [3, 7].
HIV prevalence in antenatal care (ANC) is estimated at
16% in Zimbabwe, leading to approximately 61000 births per
year to HIV-infected women [8, 9]. Through 2009, the Zimba-
bwe National PMTCT Program provided single-dose NVP
(sdNVP) to all HIV-infected women, with ART for women
identiﬁed clinically as ART eligible [8]. Like most countries in
sub–Saharan Africa, Zimbabwe initially implemented the
revised WHO guidelines with Option A (with antenatal cover-
age of 46% in 2010) and will soon be examining the feasibility
of Options B and B+ [4]. We used validated computer models
of HIV disease and PMTCT [10–12] to project the clinical
outcomes and cost effectiveness of implementing WHO-rec-
ommended PMTCT regimens in Zimbabwe.
METHODS
Analytic Overview
We used 3 validated, linked computer models for this analysis
(Figure 1): (1) a model of a single pregnancy and delivery (the
mother-to-child HIV transmission [MTCT] model [10]); (2) the
Cost-effectiveness of Preventing AIDS Complications (CEPAC)
model of HIV infection and mortality among breastfed infants
(the CEPAC infant model [13, 14]); and (3) the CEPAC-Interna-
tional model of HIV disease progression among postpartum
women (the CEPAC adult model [11,12,15]). Clinical outcomes
of the linked models included infant HIV infection risk at
weaning, maternal life expectancy (LE) from delivery, and infant
LE from birth. Economic outcomes, from the healthcare system
perspective, included ANC costs (through delivery), maternal
HIV-related healthcare costs, and infant healthcare costs.
Incremental cost-effectiveness ratios (ICERs), in US dollars
per year of life saved (YLS), were calculated from combined
projected lifetime healthcare costs (antenatal+ maternal +
infant) and combined projected life expectancy (maternal +
infant) [16], discounted at 3% per year. We used 2 criteria to
interpret cost-effectiveness. First, following WHO guidance,
an intervention was considered cost-effective if its ICER com-
pared with the next least-expensive alternative was <3 times
the 2008 Zimbabwe per capita gross domestic product, or
3 ×$400= $1200 per YLS [17, 18]. Second, we compared
results with the recently reported range of ICERs for ART-
related interventions in developing countries ($550–$5200 per
YLS) [19]. This work was approved by the Partners Healthcare
Institutional Review Board, Boston, Massachusetts.
Modeled Population, PMTCT Regimens, and Uptake of PMTCT
Services
The linked models were used to simulate a cohort of pregnant,
HIV-infected women in Zimbabwe and their infants. We ex-
amined 5 PMTCT regimens: (1) no antenatal ARVs (compar-
ator), (2) sdNVP, (3) WHO Option A, (4) WHO Option B,
and (5) Option B+ (Supplementary Table 1). Women were
modeled to present to care at 24–28 weeks’ gestation and to
breastfeed for 18 months, based on Zimbabwean data [20, 21],
with ARV prophylaxis (Options A, B, and B+ ) continued
throughout breastfeeding.
To demonstrate the impact of guideline-concordant care, all
women in the base-case analyses were assumed to be identi-
ﬁed as HIV-infected at their ﬁrst ANC visit. With no ARVs,
women received no antiretroviral medications during pregnan-
cy. With sdNVP, women initiated ART in pregnancy if clinical
assessment indicated WHO stage 3–4 disease; CD4 testing
was not included, reﬂecting its limited availability in the
sdNVP-based National PMTCT Program in 2009. With
Options A and B, women received ART during pregnancy if
eligible by either CD4 or clinical criteria, and with Option B+,
all women received lifelong ART. With all modeled regimens,
women who linked to postnatal HIV care were assumed to
undergo clinical and CD4 assessment at 6 weeks postpartum
and to initiate ART if eligible, regardless of antenatal regimen
received. In the base case, we assumed 100% adherence to
PMTCT regimens (initiated at 30 weeks’ gestational age),
100% linkage to postnatal care for mothers and infants, and
100% retention in care and ART availability for women and
infants meeting WHO ART initiation criteria [22, 23]. In sen-
sitivity analyses, to reﬂect real-world programs, we examined
reduced access to antenatal and postnatal care.
HIV/AIDS ￿ CID 2013:56 (1 February) ￿ 431Figure 1. Model structure. Three linked models were used for this analysis, as described in the Methods, as well as in the Supplementary Appendix and previous work [10, 14, 15]. The mother-to-child
human immunodeﬁciency virus transmission model includes events during pregnancy and delivery (left panel; Supplementary Figure 1). The Cost-effectiveness of Preventing AIDS Complications (CEPAC)
adult model includes events occurring among mothers after delivery (bottom right panel; Supplementary Figure 2A), and the CEPAC infant model includes events for infants after birth (top right panel;
Supplementary Figure 2B). Linkages between the models allow a combined analysis in which each woman–infant pair is simulated together from the time of ﬁrst presentation at antenatal care through
pregnancy and delivery, and then each woman and infant are simulated separately throughout their lifetimes. Abbreviations: ANC, antenatal care; ART, 2-drug antiretroviral therapy; ARVs, antiretroviral
medications; HIV, human immunodeﬁciency virus; OI, opportunistic infection; PMTCT, prevention of mother-to-child HIV transmission; sdNVP, single-dose nevirapine.
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The 3 simulation models are described in detail in the Supple-
mentary Appendix and in previous publications [10, 14, 15].
The models were linked so that each mother–infant pair was
simulated together from the time of ﬁrst presentation at ANC
through delivery (the MTCT model), and then each woman
and infant were simulated separately over their lifetimes after
delivery (the CEPAC adult and infant models), as in Figure 1
and Supplementary Figures 1 and 2.
Model Input Parameters
Maternal Characteristics, Disease Progression, and ART
Based on Zimbabwean data, mean age at ﬁrst ANC visit was
24 years [21]; mean CD4 count was 451 cells/µL (36% of
women with CD4 count ≤350 cells/µL) [24]. Because detailed
data to inform monthly risks of opportunistic infections
(OIs) and HIV-related death in the absence of ART were not
available from Zimbabwe, we derived these data from a cohort
in South Africa (Supplementary Table 2)[ 25]. Details of
ART initiation and switching, as well as CD4 and HIV RNA
changes on ART, are provided in the Supplementary
Appendix.
MTCT Risks, Infant Mortality Rates, and Infant Life
Expectancy Estimates
Risks of MTCT during pregnancy and breastfeeding were calcu-
lated from PMTCT studies among breastfeeding populations in
Africa, leading to estimates similar to those derived by the Joint
United Nations Programme on HIV/AIDS (Supplementary Ap-
pendix)[ 10, 26]. Data and assumptions to inform infant mor-
tality rates and LE values are shown in Table 1 and detailed in
the Supplementary Appendix.
Cost Inputs
Monthly medication costs were from the Clinton Healthcare
Access Initiative [27]. Costs of clinical care were determined
by estimating resource utilization (number of inpatient days
and outpatient visits) for speciﬁed health conditions, then
multiplying by the estimated costs of these healthcare encoun-
ters in Zimbabwe (Table 1 and Supplementary Appendix)[ 28].
For children aged >18 months, monthly utilization estimates
(stratiﬁed by HIV and ART status) were multiplied by LE to
estimate lifetime healthcare costs.
Model Validation and Sensitivity Analyses
Model-derived risks of MTCT, infant mortality, and postpar-
tum maternal OIs were validated against published data, re-
ported previously with extensive sensitivity analyses [10, 14].
For this study, we conducted univariate and multivariate sen-
sitivity analyses on key PMTCT, pediatric, maternal, and cost
parameters.
Access to Care Parameters
We examined the impact of reported rates of PMTCT uptake,
deﬁned as the proportion of HIV-infected women receiving
PMTCT services and ARVs by delivery (56%, estimated for
Zimbabwe in 2009; 80%, the 2009 WHO target goal; 90%, the
2011 WHO target goal; and 95%, reported in neighboring Bo-
tswana in 2011) [5, 8, 29]. We varied the availability of CD4
assays from 25% to 100% in Options A, B, and B+; when CD4
count was unavailable in Option A, women were assumed to
initiate ART only for WHO stage 3–4 disease. We also exam-
ined the impact of reduced pediatric ART availability (36%,
estimated for Zimbabwe in 2009) [5] and of reported rates of
maternal loss to follow-up (LTFU) from postnatal HIV care
(Table 1)[ 30–32].
Clinical Health Parameters
We deﬁned a lowest-MTCT risk scenario, using the lowest
published risks (best reported effectiveness/efﬁcacy) for each
modeled regimen (Table 1); a highest-MTCT risk scenario,
combining the highest published risks for each regimen; and a
scenario assuming equal MTCT risks with Options A and
B. We also used 4 assumptions about LE for HIV-exposed
and HIV-infected infants: (1) a high pediatric LE scenario,
using the upper bound estimates shown in Table 1, (2) a low
pediatric LE scenario, using the lower bound estimates, (3) a
largest difference scenario (lowest estimates for HIV-infected
children; highest estimates for HIV-uninfected children), and
(4) a smallest difference scenario (highest estimates for HIV-
infected children; lowest estimates for uninfected children).
Finally, we investigated potential maternal health impacts of
Option B and B+ in 2 ways. First, we varied the efﬁcacy of ﬁrst-
line ART when resumed after ART interruption, reﬂecting
potential interruption-associated drug resistance. Next, we ex-
amined the impact of “treatment fatigue” for women who begin
ART with CD4 count >350 cells/µL solely for PMTCT, modeled
as (1) an increased risk of virologic failure >6 months after ART
initiation or (2) a reduction in second-line ART efﬁcacy.
Cost Parameters
Because estimated costs of healthcare in Zimbabwe are mark-
edly lower than in surrounding countries [28], we repeated the
analysis using costs from South Africa (Supplementary
Table 2)[ 33]. In the base case, we conservatively assigned life-
long costs of NVP-based ART to HIV-infected infants; in sen-
sitivity analyses, as an upper bound on pediatric ART costs,
we assigned the costs of lifelong lopinavir/ritonavir-based
ART to sdNVP-exposed, HIV-infected children. Finally, the
nondrug costs of providing 3-drug ARV regimens instead of
zidovudine alone (e.g., personnel, laboratory costs) have not
been reported; we also examined the impact of such imple-
mentation costs in the antenatal period.
HIV/AIDS ￿ CID 2013:56 (1 February) ￿ 433Table 1. Selected Model Input Parameters
Variable Value Data Sources
Clinical Model Input Parameters
Baseline Maternal Cohort Characteristics
Age, mean, y (SD) 24 (5) MOHCW [21]
Mortality during pregnancy 0.7% MOHCW [8]
Proportion ART eligible
a 36% ZVITAMBO trial [24]
CD4 count, cells/µL (SD)
Total cohort 451 (50) ZVITAMBO trial [24]
ART-eligible women 275 (50) ZVITAMBO trial [24]
Non-ART-eligible women 550 (50) ZVITAMBO trial [24]
Uptake of PMTCT services and postnatal care
PMTCT uptake
b 100% (sensitivity analyses:
56%, 80%, 95%)
WHO [1]
Sensitivity of clinical assessment of ART
eligibility
36% MTCT-Plus Cohort [47]
Probability of linking to pediatric HIV
diagnosis, care, and ART
100% (sensitivity analysis:
36%)
WHO/UNICEF [48]
Probability of linking to postnatal maternal
HIV-related care
100% (sensitivity analyses:
87% if ANC received,
43% if no ANC received)
After ANC: Mean of
published values [49–54]
No ANC: assumption
Loss to follow-up from postnatal maternal
care
0% per year (sensitivity
analyses: 16% [year 1];
6% per year [years ≥2])
[30–32]
Base Case Value (range for sensitivity analysis)
Maternal HIV Status
Mother-to-Child Transmission Risks PMTCT Regimen Received
Intrauterine/intrapartum period (one-time risks)
No ARVs sdNVP Antenatal ZDV
c 3-Drug Regimen Data Sources
ART eligible at conception 0.273 (0.199–0.322) 0.176 (0.082–0.264) 0.136 (0.091–0.157) 0.033 (0.011–0.041) [24, 55–69]
Non-ART eligible at conception 0.175 (0.127–0.206) 0.073 (0.033–0.109) 0.036 (0.024–0.041) 0.01 (0.004–0.028) [24, 55–64][ 66, 67, 69–71]
Postnatal period (rate per 100 person-years among HIV-uninfected infants aged 4-6 weeks)
No ARVs Extended Infant NVP 3-Drug Regimen Data Sources
ART eligible 9.1 (EBF); 15.4 (MBF)
(5.7–28.4)
NA 4.0 (0–6.4) [24, 57, 59, 65, 67, 69–72]
Non-ART eligible 2.9 (EBF); 4.8 (MBF)
(1.8–8.8)
2.7 (1.4–3.7) 2.2 (0–6.4) [24, 52, 59, 67, 70–77]
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Variable Value Data Sources
Infant Mortality and Life Expectancy
Probability of live birth 95.7%–98.0% MOHCW [21]
Relative increase in infant mortality if
maternal death occurs
2-fold increase [78–81]
Short-term mortality risks, % 1-year risk 2-year cumulative risk
HIV-exposed, uninfected children 7.4 [82] 9.2 [82]
HIV-infected children, no ART
Intrauterine/intrapartum infection 51.0 [83] 65.0 [83]
Postpartum infection 24.0 [83] 38.0 [83]
HIV-infected children, on ART 9.5 [84] 12.0 [85]
Life-expectancy estimates, y Base Case Value Range for Sensitivity
Analyses
HIV-exposed, uninfected children (from
weaning)
50.0 (assumption) 43.0–67.0 [86, 87]
HIV-infected children, no ART
Intrauterine/intrapartum infection (from
birth)
1.1 [83] 1.1–2.0 (assumption)
Postpartum infection (from time of
infection)
9.4 [83] 5.0–10.0 (assumption)
HIV-infected children, on ART
Intrauterine/intrapartum infection (from
birth)
20.0 (assumption) 10.0–25.0 (assumption)
Postpartum infection (from time of
infection)
20.0 (assumption) 10.0–25.0 (assumption)
Maternal Disease Progression Parameters Value Data Source
Impact of antiretroviral therapy
Efficacy, % HIV RNA suppression at 24 wk
First-line ART, TDF/FTC+(NVP or EFV)
Initiated during pregnancy 90% [88]
Initiated postpartum, no sdNVP exposure 90% OCTANE trial [89]
Difference: [90–92]
Initiated postpartum, with sdNVP exposure 85% (difference assumed
vs no sdNVP, 5% [88])
Second-line ART (ZDV/3TC/LPV/r) 72% [93]
CD4 cell decline over 6 mo following ART
interruption
139 cells/µL [36–38]
Laboratory and medication costs 2008 US Dollars Data Sources
Economic Model Input Parameters
CD4 assay, performed once in ANC for Options
A, B, and B+
9.42 [33]
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Variable Value Data Sources
Full blood count, performed once in ANC for
Options B and B+
9.27 [94]
Single-dose NVP, 1 maternal and 1 infant dose 0.06
Antenatal ZDV, Option A
c 7.67 per month [27]
Antenatal TDF/FTC/NVP, Options B and B+,
CD4 count ≤350 cells/µL
c
12.12 per month [27]
Antenatal TDF/FTC/EFV, Options B and B+,
CD4 count >350 cells/µL
c
16.50 per month [27]
Postnatal maternal ART
First-line TDF/FTC/NVP; TDF/FTC/EFV 12.12 per month; 16.50
per month
[27]
Second line, ZDV/3TC/LPV/r 45.36 per month [27]
Pediatric ART, d4T/3TC/NVP 4.54 per month [27]
Healthcare Resource Utilization and Costs
Antenatal care 2008 US Dollars Data Sources
Routine antenatal care, 4 visits 45.77 Average of: [95, 96]
Delivery costs, healthcare facility 54.50 [96]
Routine and urgent
health care costs: Children
No. of Inpatient
Days per Year
No. of Outpatient
Visits per Year
Total Cost
per Month
d
Data Sources
HIV-infected children, on ART 2.14 6 3.32 [97]
Intrauterine/intrapartum infection, no ART 18 6 16.48 [98]
Postpartum infection, no ART, aged
0–18 mo
18 6 16.48 [98]
Postpartum infection, no ART, aged
>18 mo
11 6 10.67 [98]
HIV-exposed, uninfected children, aged
0–18 mo
1 3.5 1.73 Assumption
e
HIV-exposed, uninfected infants aged
>18 mo
0 1 0.26 Assumption
e
Terminal care, last month of life 5 0 49.80 Assumption
e
Routine and urgent health
care costs: Mothers
No. of Inpatient
Days per Event
No. of Outpatient
Visits per Event
Total Cost
per Event
d
Data Sources
Care for acute opportunistic infections Cape Town AIDS Cohort [99]
WHO stage 3–4 HIV disease, range by
specific disease
1.3–2.9 2.7–3.4 21.88–39.36
Bacterial infection 2.8 2.4 32.28
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Base-Case Results
Pediatric HIV Risk and LE
Among infants born to HIV-infected women, projected 18-
month HIV infection rates were 24.8% (no antenatal ARVs),
14.2% (sdNVP), 7.5% (Option A), and 5.7% (Options B and
B+) (Table 2). The resulting projected undiscounted LE (in-
cluding both HIV-infected and HIV-uninfected infants)
ranged from 38.35 years (no antenatal ARVs) to 44.18 years
(Options B and B+).
Pediatric Costs
PMTCT regimens that prevented more infant infections re-
sulted in lower pediatric healthcare costs over time. After the
early cost of infant NVP during breastfeeding, the pediatric
healthcare costs of Option A became less than those of no an-
tenatal ARVs by 4 years after delivery (Figure 2A). This
ﬁnding persisted over longer horizons; undiscounted lifetime
costs per infant ranged from $730 (no antenatal ARVs) to
$370 (Options B and B+) (Table 2).
Maternal LE
Among HIV-infected women, projected undiscounted mater-
nal LE from delivery was 21.25 years (no antenatal ARVs),
21.26 years (Option A), and 22.42 years (Option B+). Project-
ed maternal LE was lowest in the sdNVP strategy (20.94 years,
due to the modeled impact of nonnucleoside reverse transcrip-
tase inhibitor resistance on subsequent ﬁrst-line ART) and in-
termediate in the Option B strategy (21.30 years, reﬂecting
beneﬁts from ART during pregnancy and breastfeeding but
interruption after weaning).
Maternal Costs
Although small differences in short-term maternal costs re-
sulted from modeled drug resistance following sdNVP, 5-year
costs were similar for no antenatal ARVs, sdNVP, and Option
A (Figure 2B). Options B and B+, requiring 3-drug regimens
during pregnancy and breastfeeding, conferred the greatest
initial maternal healthcare costs. Option B conferred lower
maternal costs than Option B+ after weaning because of de-
ferred ART costs when women without advanced disease in-
terrupted ART, and maternal costs with Option B were less
than with Option A by 5 years after delivery (Figures 2B and
2C). Undiscounted lifetime maternal HIV-related costs per
woman ranged from $8450 (Option B) to $9820 (Option B+
(Table 2).
Cost-effectiveness Analysis
Option B was projected to result in a discounted combined
lifetime cost (ANC+mother +infant) of $5630 per mother–
infant pair and a discounted combined LE (mother + infant)
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HIV/AIDS ￿ CID 2013:56 (1 February) ￿ 437of 38.32 years (Table 3). Compared with Option B, the
sdNVP, Option A, and no antenatal ARVs strategies all result-
ed in lower combined LE (36.03–37.89 years) at greater dis-
counted lifetime costs ($5710–5880 per mother–infant pair)
and were therefore “dominated.” Replacing Option B with
Option B+ would increase costs ($6620 per mother–infant
pair) and LE (39.04 years), with an ICER of $1370 per YLS.
Considering total combined costs (ANC + mother + infant),
Option B became cost saving compared with Option A by 4
years after delivery (Figure 2D; Supplementary Table 7).
Sensitivity Analyses
Access-to-Care Parameters
The ﬁnding that no antenatal ARVs, sdNVP, and Option A
were more costly but less effective than Option B was robust
with reduced uptake of PMTCT services or access to CD4
testing, as well as with current availability of pediatric ART,
and the ICER of Option B+ compared with Option B in these
scenarios remained $1370 per YLS (Table 3, Supplementary
Table 5). With reported rates of LTFU from maternal postna-
tal HIV care, the ICER of Option B+ compared with Option B
decreased to $850 per YLS. This ICER remained $850 per YLS
when current overall access to care in Zimbabwe was simulat-
ed (PMTCT uptake, 56%; pediatric ART availability, 36%;
maternal LTFU, 16% in year 1, 6% per year thereafter).
Clinical Health Parameters
Base-case policy conclusions were unchanged in all modeled
pediatric LE and MTCT risk scenarios, including when MTCT
risks were equal with Options A and B, as well as throughout
a variety of “treatment fatigue” scenarios for women initiating
3-drug regimens with CD4 count >350 cells/µL (Supplementary
Table 5). Results were sensitive, however, to the risk of virolog-
ic failure after 6 months on ART. When this risk was
increased 1.5-fold from the base case (to >2.4% per month),
Option B no longer dominated Option A; when it was in-
creased 2-fold (to 3.2% per month), Option A dominated
Option B (Table 3; Supplementary Table 5).
Cost Parameters
Policy conclusions were unchanged when lifelong lopinavir/ri-
tonavir costs were assigned to sdNVP-exposed, HIV-infected
infants (Supplementary Table 5). In sensitivity analyses using
South Africa healthcare costs, the ICER of Option B+
Table 2. Base-Case Results: Projected Maternal and Pediatric Outcomes of the Zimbabwe National Prevention of Mother-to-Child HIV
Transmission Program
18-Month Infant HIV
Infection Risk
Pediatric Life Expectancy, Years
From Birth
Maternal Life Expectancy, Years
From Delivery
Undiscounted Discounted Undiscounted Discounted
Projected Clinical Outcomes
a
No antenatal ARVs
b 24.8% 38.35 21.34 21.25 14.69
sdNVP 14.2% 41.30 22.45 20.94 14.53
Option A 7.5% 43.27 23.19 21.26 14.70
Option B 5.7% 44.18 23.59 21.30 14.74
Option B+ 5.7% 44.18 23.59 22.42 15.45
Antenatal Care Costs,
Through Delivery
Pediatric Lifetime Healthcare
Costs, From Birth
Maternal Lifetime HIV-Related
Healthcare Costs, From Delivery
Undiscounted Discounted Undiscounted Discounted
Projected costs, 2008 US Dollars
a
No antenatal ARVs
b 85 730 520 8490 5280
sdNVP 92 530 360 8460 5300
Option A 118 490 310 8500 5280
Option B 134 370 240 8450 5260
Option B+ 134 370 240 9820 6240
Abbreviations: ARVs, antiretroviral medications; HIV, human immunodeficiency virus; sdNVP, single-dose nevirapine.
a Base-case projections assume 100% uptake of PMTCT services by the time of delivery, 100% linkage to HIV care during breastfeeding, no maternal loss to
follow-up after delivery, and 100% availability of pediatric antiretroviral therapy (ART) for HIV-infected infants (see Methods).
b No antenatal ARVs refers to receipt of no ARVs or antiretroviral therapy prior to delivery. In all modeled strategies, ART-eligible women who linked to HIV-
related healthcare after delivery were assumed to receive ART for their own health in all strategies (Supplementary Table 1).
438 ￿ CID 2013:56 (1 February) ￿ HIV/AIDSFigure 2. Projected costs (in US dollars [USD]) over the ﬁrst 5 years after delivery for modeled prevention of mother-to-child human immunodeﬁciency virus (HIV) transmission (PMTCT) regimens in
Zimbabwe. A–D, Undiscounted costs are shown on the vertical axis, and time from delivery is shown on the horizontal access. A, Total healthcare costs for infants (with 100% pediatric antiretroviral
therapy [ART] availability). The costs of daily infant nevirapine (NVP) prophylaxis (Option A) are included in pediatric healthcare costs. Because infant NVP is modeled as a pediatric cost, Option A is more
expensive than the others during the ﬁrst 18 months (while breastfeeding continues). PMTCT regimens that are more effective in preventing infant infections result in slower increases in costs (ﬂatter
slopes) as time progresses because pediatric HIV care costs are averted, and the pediatric care costs following Option A become less than those following no antenatal antiretroviral medications (ARVs) by
4 years after delivery (arrow). B, HIV-related healthcare costs for women after delivery (with 100% retention in care). The costs of maternal ART and 3-drug ARV prophylaxis (Options B and B+) are included
in maternal HIV-related healthcare costs. Postnatal care costs are similar following the no antenatal ARVs, single-dose NVP (sdNVP), and Option A strategies: women enrolled in HIV-related care following
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9compared with Option B was $1410 per YLS (Table 3). The
difference in antenatal implementation costs between 3-drug
regimens and zidovudine alone needed to be ≥$150 per
person to change the comparison between Options A and B
(Table 3); at $150 per person, Option B was no longer cost
saving but remained very cost-effective ($2 per YLS), com-
pared with Option A. Even with implementation costs as high
as $400 per person, the ICER of Option B compared with
Option A remained <$400 per YLS (Supplementary Table 6).
DISCUSSION
There are 4 key ﬁndings from this work. First, a strategy of
providing no antenatal ARVs for PMTCT is more expensive
and less effective over a lifetime horizon than strategies based
on sdNVP, Option A, or Option B. This result, which occurs
because the upfront costs of these PMTCT regimens are
greatly outweighed by the downstream costs of caring for
HIV-infected infants, lends strong economic support to the
well-recognized clinical impact of expanding access to
PMTCT programs, regardless of the speciﬁc drug regimen
provided [5]. Second, in settings where 3-drug ARV regimens
are not available for PMTCT [5, 34], replacing sdNVP with
Option A beneﬁts infants and mothers and saves money over
a lifetime horizon.
Third, healthcare programs would decrease costs and
improve outcomes further by implementing Option B instead
of Option A. Although short-term drug costs are greater with
Option B, the incorporation of healthcare costs for both
mothers and infants leads Option B to cost less than Option
A within 4 years after delivery, primarily because of averted
pediatric HIV costs (Figure 2D). Notably, however, if women
with high CD4 counts develop poor adherence after Option B
(increasing the monthly risk of late virologic failure by ≥25%)
(Supplementary Table 5) or if mothers are lost to follow-up
after delivery, Option B leads to shorter projected maternal LE
than Option A.
Finally, these results strongly support lifelong ART for all
pregnant, HIV-infected women (Option B+) [3, 7]. The inter-
ruption of effective ART in Option B may have deleterious
effects on maternal health. Randomized trial data comparing
maternal health outcomes of Options B and B+ are anticipat-
ed soon [35]. In the interim, we assume a rapid rate of CD4
decline after ART interruption based on other trials [36–38],
with an associated increased risk of OIs. As a result, Option
B+ is projected to increase undiscounted maternal LE by 1.12
years compared with Option B (consistent with modeled
impacts of other HIV-related interventions [12, 39]), with an
ICER of $1370 per YLS. Although this ICER exceeds the 2008
gross domestic product–based threshold for cost-effectiveness
in Zimbabwe ($1200 per YLS) [17, 18], it falls in the lower
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440 ￿ CID 2013:56 (1 February) ￿ HIV/AIDSrange of ICERs reported for ART-related interventions in devel-
oping countries ($550–$5200 per YLS) [19] and thus represents
a return on investment comparable with many current HIV
programs in Zimbabwe and other resource-limited settings.
Option B+ may represent an even better healthcare invest-
ment compared with Option B under speciﬁc conditions.
First, ART interruption (Option B) may cause greater detri-
ment to maternal health under real-world programmatic
Table 3. Cost-effectiveness of World Health Organization 2010 Prevention of Mother-to-Child HIV Transmission Guidelines in
Zimbabwe
Modeled Scenario and
PMTCT Regimen
Combined Costs per
Mother–Infant Pair,
Discounted, 2008 US
Dollars
a
Combined Life Expectancy
per Mother–Infant Pair,
Discounted, Years From
Delivery
b
ICER, US Dollars
per YLS
Base-Case Projections
c
Base-case projections (100% PMTCT uptake, retention in postnatal maternal care, pediatric ART availability)
Option B 5630 38.32
Option A 5710 37.89 Dominated
d
sdNVP 5760 36.97 Dominated
No antenatal ARVs 5880 36.03 Dominated
Option B+ 6620 39.04 1370
Sensitivity Analyses
e
Access to care parameters:
Reduced PMTCT uptake (56% of HIV-infected women receiving ARVs by delivery; 87% linkage to postnatal care)
Option B 4930 35.69
Option A 4980 35.44 Dominated
sdNVP 5000 34.92 Dominated
No antenatal ARVs 5060 34.39 Dominated
Option B+ 5600 36.18 1370
Increased maternal loss to follow-up after delivery (16% in year 1, 6% per year thereafter)
Option B 3420 35.23
Option A 3560 34.90 Dominated
sdNVP 3620 34.06 Dominated
No antenatal ARVs 3730 33.05 Dominated
Option B+ 3910 35.81 850
Reduced pediatric ART availability (36% of infected children; 2009 Zimbabwe estimate)
Option B 5610 38.00
sdNVP 5670 35.96 Dominated
Option A 5670 37.41 Dominated
No antenatal ARVs 5690 34.06 Dominated
Option B+ 6590 38.71 1370
Current access to care (56% PMTCT uptake, 87% linkage to postnatal maternal care, increased maternal LTFU, 36% pediatric ART
availability)
Option B 3010 31.99
sdNVP 3090 30.94 Dominated
Option A 3090 31.72 Dominated
No antenatal ARVs 3100 29.83 Dominated
Option B+ 3340 32.38 850
Clinical health parameters:
“Treatment fatigue”: monthly risk of virologic failure after 6 mo on first-line NNRTI-based ART=2.39% for women starting ART with
CD4 count >350 cells/µL (Options B/B+) (1.5×base-case risk)
Option B 5700 37.82
Option A 5710 37.89 190
sdNVP 5760 36.97 Dominated
No antenatal ARVs 5880 36.03 Dominated
Option B+ 6700 38.67 1260
HIV/AIDS ￿ CID 2013:56 (1 February) ￿ 441conditions than in our guideline-concordant simulations.
When women are lost to follow-up after weaning, disease pro-
gression is unobserved and cannot lead to prompt ART reini-
tiation. Such disease progression is more rapid when ART was
interrupted months before LTFU (Option B) than at the time
of LTFU (Option B+) because of lower CD4 counts at LTFU
in Option B. As a result, Option B leads to a projected dis-
counted LE (11.64 years) even lower than no antenatal ARVs
(11.71 years) [10], and Option B+ becomes more cost-effective
compared with Option B ($850 per YLS). Second, analyses
using cost data from South Africa (ICER, $1410 per YLS; 2008
gross domestic product, $5700) [18] suggest that Option B+
may be very cost-effective compared with Option B in higher-
income settings where healthcare costs are greater. Third, this
analysis excludes several additional beneﬁts of Option B+ that
may render it even more effective and cost-effective, including
prevention of maternal tuberculosis (also reducing infection
risk in infants) [40], HIV transmission to male partners [40],
hepatitis B ﬂares due to ARV interruption [7], and MTCT
during subsequent pregnancies when women are already on
ART at conception [7].
There are several limitations to this analysis. First, all
models necessarily simplify complex processes; for example,
assumptions about infant LE involved uncertainties about
healthcare in the distant future. However, LE assumptions,
cost assumptions, and projected clinical and economic results
were similar to those previously reported [41, 42], and we
tested the impact of biologic and operational assumptions in
extensive sensitivity analyses [10, 14]. Except where noted, the
impact on policy conclusions was minimal, primarily because
assumptions were consistent across PMTCT strategies.
Second, we excluded the potential impact of drug-related viral
resistance in infants who become infected despite exposure to
modeled ARV regimens, because of limited data about acqui-
sition of such resistance [43, 44] and its impact on later ART
effectiveness. If resistant HIV is a greater concern for infants
who become infected while exposed to maternal ARVs
through breastmilk than to extended NVP monoprophylaxis,
the beneﬁts of Options B and B+ vs Option A will be attenu-
ated. Finally, our analysis assumed a healthcare system per-
spective. If a societal perspective were assumed, interventions
that avert HIV infections in infants and prevent morbidity
and mortality in women would be even more cost-effective,
avoiding transportation costs and lost wages for medical care
and permitting the productivity gains of healthy women and
of children who will become healthy adults.
Table 3 continued.
Modeled Scenario and
PMTCT Regimen
Combined Costs per
Mother–Infant Pair,
Discounted, 2008 US
Dollars
a
Combined Life Expectancy
per Mother–Infant Pair,
Discounted, Years From
Delivery
b
ICER, US Dollars
per YLS
Resource utilization parameters:
South Africa healthcare costs
Option B 14040 38.33
Option A 14260 37.89 Dominated
sdNVP 14730 36.97 Dominated
Option B+ 15070 39.05 1410
No antenatal ARVs 15520 36.04 Dominated
Additional $150 antenatal implementation cost for 3-drug regimens compared with ZDV alone
Option A 5760 37.89
Option B 5760 38.32 2
sdNVP 5770 36.97 Dominated
No ARVs 5880 36.03 Dominated
Option B+ 6750 39.04 1370
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral medications; HIV, human immunodeficiency virus; ICER, incremental cost-effectiveness ratio; LTFU,
lost to follow-up; NNRTI, nonnucleoside reverse transcriptase inhibitor; PMTCT, prevention of mother-to-child transmission; sdNVP, single-dose nevirapine; YLS,
year of life saved; ZDV, zidovudine.
a Combined costs=PMTCT program costs+ maternal lifetime HIV-related healthcare costs+ infant lifetime healthcare cost (per mother–infant pair).
b Combined life expectancy = maternal life expectancy from delivery +infant life expectancy from birth.
c Base-case results. Base-case projections assume 100% uptake of PMTCT services by the time of delivery, 100% linkage to HIV care during breastfeeding,n o
maternal loss to follow-up after delivery, and 100% availability of pediatric ART for HIV-infected infants.
d Dominated refers to an intervention that is more expensive and less effective than an alternative intervention.
e Sensitivity analyses. Please see Supplementary Table 5 for additional details regarding all sensitivity analyses, including the distribution of costs and life
expectancy between mothers and infants.
442 ￿ CID 2013:56 (1 February) ￿ HIV/AIDSAs in other studies, we ﬁnd that PMTCT programs based on
sdNVP are cost saving, compared with no PMTCT interven-
tions [45]. This is the ﬁrst analysis to compare sdNVP and
Options A, B, and B+ and to consider both short- and long-
term maternal and infant outcomes after PMTCT [16, 41, 42,
45]. We ﬁnd that, with guideline-concordant care, Option A is
cost saving compared with sdNVP; Option B becomes more ef-
fective and less expensive than Option A within 4 years of de-
livery; and Option B+ offers additional clinical beneﬁts and
economic value comparable with other widely used HIV inter-
ventions. We anticipate that the clinical results of these analyses
will be generalizable to many African settings where prolonged
breastfeeding is the norm and that the base-case economic
results may also be applicable in low-income African countries
with healthcare costs similar to Zimbabwe. Although speciﬁc
policies will depend on available resources as well as important
considerations of fairness, feasibility, and priority populations
[15, 46], PMTCT programs should move rapidly toward these
more effective and economically efﬁcient strategies.
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